23:31 , Oct 3, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious

INDICATION: HIV/AIDS...
21:49 , Jan 8, 2018 |  BC Innovations  |  Distillery Therapeutics

Musculoskeletal

INDICATION: Osteoporosis Mouse studies suggest CCR5 inhibitors could help treat osteoporosis. In a mouse model of osteoporosis, systemic knockout of CCR5 decreased trabecular bone loss in the femur compared with normal expression. Next steps could...
01:26 , Nov 28, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Patient sample and mouse studies suggest inhibiting CCR5 or its interactions with CCL3, CCL4 and RANTES could help treat melanoma. In patient tissue samples, the number of CCR5-positive myeloid-derived suppressor cells (MDSC) and...
20:37 , May 4, 2017 |  BC Innovations  |  Translation in Brief

Tethered hope

A Scripps team has developed a method for identifying antiviral, membrane-tethered antibodies that block virus-host receptor interactions without disrupting normal receptor functions, a strategy that could both reduce the ability of the virus to develop...
08:00 , Nov 19, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: μ opioid receptor (MOR; OPRM1); CC chemokine receptor 5 (CCR5; CD195)

Neurology INDICATION: Pain In vitro and mouse studies suggest a conjugate of an MOR agonist and a CCR5 antagonist could help treat inflammation-associated pain. The conjugate consisted of the generic MOR agonist oxymorphone and a...
08:00 , Jan 8, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: CC chemokine receptor 5 (CCR5; CD195)

Cancer INDICATION: Prostate cancer Mouse studies suggest CCR5 antagonists could help prevent prostate cancer metastasis. In mouse models of metastatic prostate cancer, the CCR5 antagonist Selzentry maraviroc decreased metastatic burden by 80% in bone and...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Clinical News

Selzentry: Phase III data

The 96-week, double-blind, double-dummy, international Phase III MODERN trial in 797 antiretroviral-naive patients with CCR5-tropic HIV-1 infection showed that once-daily 150 mg maraviroc plus darunavir/ritonavir missed the primary endpoint of non-inferiority to once-daily Truvada emtricitabine/tenofovir...
07:00 , Oct 10, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Crystal structure of Selzentry maraviroc-bound HIV-1 co-receptor CC chemokine receptor 5 (CCR5; CD195) The crystal structure of HIV-1 co-receptor CCR5 bound by the allosteric inhibitor...
07:00 , Oct 10, 2013 |  BC Innovations  |  Tools & Techniques

Seeing CCR5

Despite offering a new mechanism for inhibiting HIV, Selzentry maraviroc 's sales have languished. Pfizer Inc. 's CC chemokine receptor 5 antagonist does not block viruses with tropism for another co-receptor, CXC chemokine receptor 4...
08:00 , Jan 10, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Staphylococcus CC chemokine receptor 5 (CCR5; CD195) Cell culture and mouse studies suggest inhibiting CCR5 could help treat Staphylococcus aureus...